Optos held a seminar in London last week to present the benefits of ultra-widefield (UWF) imaging in screening diabetic retinopathy and post its latest financial results.
All but three per cent of the Scottish retinal imaging firm’s sales were now outside the UK, but the company’s boss praised domestic eye screening services for diabetes patients.
Roy Davis, CEO of Optos, told Optician: ‘The UK is one of the leading places for diagnosis [of diabetes]. People look at it as a model for what they would look like.
‘Globally people are looking to do more screening because all healthcare budgets are under pressure.’
For the six months ended March 31, Optos reported headline revenue of $72.7m, up 8 per cent on an underlying basis.
During the period the company added 628 new customers and grew its overall installed base of UWF devices by 10 per cent.
It said Daytona continued to be well-received by the market and was the main driver of our new customer growth. Since its market launch two years ago, the company has placed 2,046 Daytona devices, which now represent over 30% of the company’s installed base.
Davis added: ‘We are pleased to report another strong increase in the number of new customers and our installed base of devices, principally as a result of Daytona’s continuing traction in the market place. Our financial discipline has allowed us to achieve this while keeping costs flat resulting in improved cash flow and a marked reduction in net debt, a trend we expect to continue.’